Camp4 Therapeutics's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Camp4 Therapeutics (CAMP) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Camp4 Therapeutics vs Its Competitors
- TTM: Trailing 12-month revenue of 4M vs 8,243M combined for tracked competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+68.8% annualized vs trailing 12 months), vs accelerating (+7.6%) for its tracked peer group.
- Growth: Camp4 Therapeutics generated 18.8% revenue growth year over year in Q2 2026, vs 18.3% for its tracked competitors combined.
- Profitability: Its -1,884.8% net margin compares with -16.2% for the peer group.
- Scale: Camp4 Therapeutics ranks #247 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Camp4 Therapeutics accounted for 0.1% of combined revenue among its tracked peer group, up from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.09M compares with $0.32M for the peer group (0.3x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CAMP Sales vs. its Competitors, Q2 2026
Camp4 Therapeutics reported revenue growth of 18.84 % year on year in Q2 2026, above its competitors' combined revenue growth of 18.31 %.
With a net margin of -1,884.77 %, Camp4 Therapeutics reported lower profitability than its competitors (-16.21 %).
Camp4 Therapeutics generated 0.08 % of the combined sales of its peer group, up from 0.08 % a year earlier.
Camp4 Therapeutics vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Camp4 Therapeutics and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Camp4 Therapeutics Corporation | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Camp4 Therapeutics's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 18.8% for Camp4 Therapeutics. Camp4 Therapeutics's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Camp4 Therapeutics's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Camp4 Therapeutics Corporation | No | - | - | No |
| Competitors combined (8) | ||||
| High-Confidence Competitors (6) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CAMP Stock Performance relative to its Competitors
CAMP Stock Performance relative to High-Confidence Competitors
CAMP Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Iridium Communications Inc | 282.9% | Outperformed |
| 2 | Planet Labs Pbc | 282.9% | Outperformed |
| 3 | Kvh Industries Inc | 282.9% | Outperformed |
| 4 | Sps Commerce Inc | 282.9% | Outperformed |
| 5 | Trimble Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Camp4 Therapeutics's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Camp4 Therapeutics's Comment on Competition and Industry Peers
Publicly Traded Peers of Camp4 Therapeutics Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Camp4 Therapeutics Corporation | 220.71 | 4.22 |
| Trimble Inc | 13,362.55 | 3,432.50 |
| Bentley Systems Incorporated | 9,954.67 | 1,602.17 |
| Procore Technologies Inc | 7,391.39 | 1,422.78 |
| Planet Labs Pbc | 5,721.88 | 334.07 |
| Iridium Communications Inc | 5,229.24 | 887.27 |
| SUBTOTAL | 45,038.92 | 9,035.57 |
Sign in to see all competitors of Camp4 Therapeutics Corporation.
Sources: Camp4 Therapeutics Corporation's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Camp4 Therapeutics Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Camp4 Therapeutics's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| iECURE, Inc. | Named by the company | 85% |
| Tevard Biosciences, Inc. | Named by the company | 85% |
| Arcturus Therapeutics Holdings Inc. | Named by the company | 85% |
| Regel Therapeutics, Inc. | Named by the company | 85% |
| Acadia Pharmaceuticals Inc. | Named by the company | 85% |
| Praxis Precision Medicines, Inc. | Named by the company | 85% |
| Ultragenyx Pharmaceutical Inc. | Named by the company | 85% |
| GondolaBio LLC | Named by the company | 85% |
| Stoke Therapeutics, Inc. | Named by the company | 85% |
| Amgen Inc. | Named by the company | 85% |
| Quiver Bioscience Inc. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Camp4 Therapeutics's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Camp4 Therapeutics's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Camp4 Therapeutics Corporation | R&D 100.00 % |
| Trimble Inc | Field Systems 49.88 % |
| Kvh Industries Inc | Reportable 100.00 % |
| Comtech Telecommunications Corp | Allerium 52.61 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Camp4 Therapeutics's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Camp4 Therapeutics Corporation | 221 | 87,833 | -2,234,250 |
| Trimble Inc | 13,363 | 298,478 | -9,104 |
| Bentley Systems Incorporated | 9,955 | 276,236 | 49,969 |
| Procore Technologies Inc | 7,391 | 321,823 | -8,794 |
| Planet Labs Pbc | 5,722 | 334,075 | -249,440 |
| Iridium Communications Inc | 5,229 | 910,019 | 95,656 |
| PEERS TOTAL | 44,818 | 319,966 | 1,344 |
Sign in to see all peers for Camp4 Therapeutics Corporation.
Camp4 Therapeutics's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Trimble Inc | North America 66.43 % |
| Bentley Systems Incorporated | United States, Canada, and Latin America 53.29 % |
| Procore Technologies Inc | United States 84.37 % |
| Planet Labs Pbc | North America 42.93 % |
| Comtech Telecommunications Corp | United States Domestic 55.14 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Camp4 Therapeutics's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Camp4 Therapeutics's industry classification, broader than the peer set above. Market cap in millions of $.Camp4 Therapeutics ranks #247 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 824, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,054,271 | 19.27 % |
| 2 | Johnson and Johnson | 662,243 | 12.10 % |
| 3 | Beone Medicines Ltd | 543,752 | 9.94 % |
| 4 | Abbvie Inc | 473,291 | 8.65 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 247 | Camp4 Therapeutics Corporation | 221 | 0.00 % |
Market cap and industry share for the rest of Camp4 Therapeutics's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-29.
Camp4 Therapeutics's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 242 | Akebia Therapeutics Inc | 242 | -67.27 % |
| 243 | Nature s Sunshine Products inc | 234 | -19.73 % |
| 244 | Sionna Therapeutics Inc | 230 | -82.41 % |
| 245 | Lyell Immunopharma Inc | 225 | -25.02 % |
| 246 | Keros Therapeutics Inc | 1,234 | 12.3% |
| 247 | Camp4 Therapeutics Corporation | 221 | 27.85 % |
| 248 | An2 Therapeutics Inc | 1,234 | 12.3% |
| 249 | Cartesian Therapeutics Inc | 1,234 | 12.3% |
| 250 | Oramed Pharmaceuticals Inc | 1,234 | 12.3% |
| 251 | Sol gel Technologies Ltd | 1,234 | 12.3% |
| 252 | Nkarta Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Camp4 Therapeutics's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-29. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Camp4 Therapeutics's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | - | 64.89 % (avg) | - |
| Operating Margin | -1,254.22 % | industry median | -1,200.5 pp |
| EBITDA Margin | -1,681.48 % | -7.21 % (avg) | -1,674.3 pp |
| Capital Intensity (Capex / Revenue) | - | 4.92 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Camp4 Therapeutics's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 6.9x | 4.5x | +2.5x |
| Return on Equity | -314.08 % | industry aggregate | -331.33 % |
| Return on Invested Capital | -42.80 % | -2.95 % (avg) | -39.85 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Camp4 Therapeutics's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2014 | 2015 | 2017 | 2018 | 2019 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | 7.49 % | 14.64 % | 5.82 % | 4.52 % | -2.82 % | - | - |
| Operating Margin | 8.61 % | 11.49 % | 0.69 % | 1.66 % | 0.05 % | - | -1,502.43 % |
| Return on Invested Capital | 7.40 % | 7.95 % | 0.46 % | 0.95 % | 0.03 % | -85.34 % | -41.86 % |
| P/E | - | 0.1x | 0.1x | 0.5x | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Camp4 Therapeutics's BCG Growth-Share Matrix
Relative market share (vs Camp4 Therapeutics's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Camp4 Therapeutics falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Camp4 Therapeutics's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 824 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Camp4 Therapeutics's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Camp4 Therapeutics's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Camp4 Therapeutics's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Camp4 Therapeutics falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Camp4 Therapeutics's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+68.8% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 1,200.5 points below the industry median.
- Return on equity 331.3 points below the industry aggregate.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Camp4 Therapeutics's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Camp4 Therapeutics Corporation | 6.26 | 6.49 | - |
| Trimble Inc | 0.17 | 1.02 | 0.25 |
| Bentley Systems Incorporated | 0.14 | 0.57 | 1.01 |
| Procore Technologies Inc | 0.51 | 1.23 | - |
| Planet Labs Pbc | 1.06 | 2.35 | 0.95 |
| Iridium Communications Inc | 1.05 | 2.70 | 3.83 |
Sign in to see all peers for Camp4 Therapeutics Corporation.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Camp4 Therapeutics's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Camp4 Therapeutics Corporation | Q2 2026 | +18.8 % | - |
| Trimble Inc | Q2 2026 | +28.2 % | - |
| Bentley Systems Incorporated | Q2 2026 | +13.0 % | +11.4 % |
| Procore Technologies Inc | Q2 2026 | +16.1 % | - |
| Planet Labs Pbc | Q1 2026 | +42.4 % | - |
| Iridium Communications Inc | Q2 2026 | +5.3 % | -55.9 % |
| PEERS TOTAL | +16.9 % | - |
Sign in to see all peers for Camp4 Therapeutics Corporation.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Camp4 Therapeutics's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Camp4 Therapeutics Corporation | Q2 2026 | - | - |
| Trimble Inc | Q2 2026 | +85.7 % | +20.3 % |
| Bentley Systems Incorporated | Q2 2026 | +8.8 % | +88.6 % |
| Procore Technologies Inc | Q2 2026 | +12.6 % | +15.6 % |
| Planet Labs Pbc | Q1 2026 | +48.3 % | +83.0 % |
| Iridium Communications Inc | Q2 2026 | - | +5.4 % |
Sign in to see all peers for Camp4 Therapeutics Corporation.
Camp4 Therapeutics's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Camp4 Therapeutics Corporation | - | - | - |
| Trimble Inc | - | - | - |
| Bentley Systems Incorporated | 8.21% | 11.19% | 24.09% |
| Procore Technologies Inc | - | - | - |
| Planet Labs Pbc | - | - | - |
| Iridium Communications Inc | 3.66% | 3.69% | 20.12% |
Sign in to see all peers for Camp4 Therapeutics Corporation.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Camp4 Therapeutics's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Camp4 Therapeutics Corporation | - | 52.35 |
| Trimble Inc | - | 3.89 |
| Bentley Systems Incorporated | 35.07 | 6.21 |
| Procore Technologies Inc | - | 5.20 |
| Planet Labs Pbc | - | 17.13 |
| Iridium Communications Inc | 55.41 | 5.89 |
| PEERS AVERAGE | - | 4.98 |
Sign in to see all peers for Camp4 Therapeutics Corporation.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.